A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab
Prasad S. Adusumilli(Memorial Sloan Kettering Cancer Center), Michel Sadelain(Columbia University Irving Medical Center)
Cited by 551
Related Papers
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Gene therapy comes of age
|Science|2018|1.4k
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
|Journal of Clinical Investigation|2016|1k
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
|Nature Medicine|2022|308